Journal of Orthopaedic Science

, Volume 17, Issue 3, pp 313–318 | Cite as

Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy

  • Yoshitomo Kajino
  • Tamon Kabata
  • Koji Watanabe
  • Hiroyuki Tsuchiya
Case Report

References

  1. 1.
    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–99.PubMedCrossRefGoogle Scholar
  2. 2.
    Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1555–65.PubMedCrossRefGoogle Scholar
  4. 4.
    Sayed-Noor AS, Sjödén GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467(7):1921–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010;362(19):1825–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009;122(2 Suppl):S14–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2010;468(7):1991–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89(3):349–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39(2):224–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358(12):1304–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301.PubMedCrossRefGoogle Scholar
  12. 12.
    Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010;72(2):161–8.CrossRefGoogle Scholar
  13. 13.
    Somford MP, Geurts GF, den Teuling JW, Thomassen BJ, Draijer WF. Long-term alendronate use not without consequences? Int J Rheumatol. 2009.Google Scholar
  14. 14.
    Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–41.PubMedCrossRefGoogle Scholar
  15. 15.
    Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008;359(3):316–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Japanese Guidelines for the Prevention and Treatment of Osteoporosis 2006 edition. Life Science Publishing, Tokyo, 2006:73–102 (in Japanese).Google Scholar
  17. 17.
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.PubMedCrossRefGoogle Scholar
  18. 18.
    Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010;92(5):679–86.PubMedCrossRefGoogle Scholar
  19. 19.
    Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24(10):1736–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Lee P, Seibel MJ. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008;359(3):317.PubMedGoogle Scholar
  21. 21.
    Sims SH. Subtrochanteric femur fractures. Orthop Clin North Am. 2002;33(1):113–26.PubMedCrossRefGoogle Scholar
  22. 22.
    Online version of Gray’s anatomy. Available at http://www.bartleby.com/107/59.html. Accessed Oct 20, 2010.
  23. 23.
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15(4):613–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Medicines and Healthcare Products Regulatory Agency (MHRA). Bisphosphonate: atypical stress fractures. Drug safety update 2 (8). Available at http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON041211. Accessed Oct 13, 2010.
  25. 25.
    Lin JH, Duggan DE, Chen IW, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos. 1991;19(5):926–32.PubMedGoogle Scholar
  26. 26.
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, LE Wehren, Lombardi A, Santora AC, Cummings SR, FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38.PubMedCrossRefGoogle Scholar
  27. 27.
    Noth I, Strek ME, Leff AR. Churg–Strauss syndrome. Lancet. 2003;361:587–94.PubMedCrossRefGoogle Scholar
  28. 28.
    Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24(6):1095–102.PubMedCrossRefGoogle Scholar
  29. 29.
    Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC, Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–71.PubMedCrossRefGoogle Scholar
  30. 30.
    Dobnig H, Stepan JJ, Burr DB, Li J, Michalská D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res. 2009;24(12):1998–2006.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Orthopaedic Association 2011

Authors and Affiliations

  • Yoshitomo Kajino
    • 1
  • Tamon Kabata
    • 1
  • Koji Watanabe
    • 1
  • Hiroyuki Tsuchiya
    • 1
  1. 1.Department of Orthopaedics SurgeryGraduate School of Medical Sciences, Kanazawa UniversityKanazawaJapan

Personalised recommendations